![autologous stem cell transplant autologous stem cell transplant](https://www.hematologyadvisor.com/wp-content/uploads/sites/14/2019/01/stemcellresearchg548553265_1500744.jpg)
All patients underwent complete laboratory assessments, total-body computed tomography (CT) scans, and cardiac and pulmonary function tests. First-line treatment with immunomodulatory drugs, proteasome inhibitors and dexamethasone for multiple myeloma, and anthracycline-based protocols for lymphomas, followed by mobilisation therapy (favouring stem cell release into peripheral blood) with a high dose of cyclophosphamide was carried out. Between March 2008 and August 2015, we prospectively analysed 81 consecutive patients eligible for ASCT for haematological diseases. Nonetheless, all patients signed an informed consent form. No ethics committee approval was required as this was an observational study. The aim of our study was to assess whether baseline pulmonary function tests help to define the risk of pulmonary complications/adverse events or death after ASCT, and determine whether pneumotoxic induction treatment affects this risk. Many reports focus on allogenic transplantation alone, but the only report dealing with ASCT displayed a 25% prevalence of pulmonary complications within the first year post-ASCT and a severe associated risk of death. The underlying disease and baseline pulmonary function, along with conditioning regimens consisting of carmustine, etoposide, aracytin and melphalan for lymphoma, melphalan alone for multiple myeloma or busulpan and cyclophosphamide for acute myeloid leukaemia, all concur to cause pulmonary complications. Overall, pulmonary complications, both infectious and non-infectious, occur in 40–60% of patients after stem cell transplantation, and are usually classified as early or late onset, depending on whether they occur within 100 days of the transplant. Immune system impairment and chemotherapies significantly increase the risk of infections, particularly pneumonia. If you feel unwell and are unable to contact the hospital, ask someone to take you to the nearest hospital accident and emergency (A&E) straight away.Autologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma patients eligible for high-dose therapy, lymphoma patients undergoing second-line treatments and for acute myelogenous leukaemia (AML).
![autologous stem cell transplant autologous stem cell transplant](https://i.pinimg.com/originals/d0/bd/a1/d0bda15fe0367404dbbcccc017937321.gif)
It is important to follow any specific advice your cancer treatment team gives you. you have been in contact with someone who has an infectious disease, for example chickenpox or measles.
![autologous stem cell transplant autologous stem cell transplant](https://multiplesclerosisnewstoday.com/wp-content/uploads/2018/12/stem-cell_shutterstock_240851386-1024x640.jpg)
![autologous stem cell transplant autologous stem cell transplant](https://www.differencebetween.com/wp-content/uploads/2020/01/Difference-Between-Autologous-and-Allogeneic-Stem-Cell-Transplant-Tabular-Form.jpg)
You can also use Macmillan’s Online Community to meet people who are going through similar experiences to you. Talk to the staff at the hospital where you are having your treatment. Some people find it helps to talk to someone who has already had this treatment. Most units also have a nurse specialist, a transplant co-ordinator, a social worker or a counsellor who you can talk to. You may want to talk about it with family and close friends. It is important to discuss any questions you have with your cancer doctor. You need to think about the benefits and risks of this treatment carefully before you decide. They will tell you about the possible benefits and risks. Your cancer doctor, nurse or transplant co-ordinator will explain why you are being offered this treatment.